SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...

Recursion Pharma is an AI-driven drug developer that boasts supercomputers designed to shorten drug development timelines and enhance successful outcomes. Many such companies have raised substantial ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

The up-to-$12 billion artificial intelligence (AI) drug discovery collaboration of Recursion, Roche, and its Genentech subsidiary marked a milestone Wednesday when plans were announced for Recursion ...

Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." Gibson will transition to ...

SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...